Literature DB >> 22042019

Genetic determinants of uveal melanoma.

Jérôme Couturier, Simon Saule.   

Abstract

Uveal melanoma (UM) arises from neural crest-derived melanocytes of the choroid and the ciliary body. About 50% of patients develop metastatic disease despite efficient control of the primary tumor. For about 15 years, cytogenetic and, recently, genome-wide analysis techniques have shown that UM can be classified into 2 genomic groups correlating with prognostic clinicopathologic features: class 1 tumors, with a low risk of metastases, typically characterized by a gain of the 6p chromosome arm, often associated with a gain of the distal part of the 8q chromosome arm, and class 2 tumors, with a high metastatic risk, presenting loss of the entire chromosome 3 and gain of the entire 8q, related to the formation of isochromosomes. Genome-wide expression profiling has proved to be a powerful tool for separating these 2 classes. However, despite advances in the genomic and prognostic characterization of UM, the knowledge of pathways deregulated in these tumors is just emerging and, in contrast to cutaneous melanoma, no major predisposing genes are known. Altered or deregulated genes are reviewed in this chapter. Inactivating mutations have recently been identified by exome sequencing in gene BAP1, mapping to 3p21.1, in class 2 tumors. Among other discriminant genes identified from genome-wide expression profiling, PTP4A3, mapping to 8q24.3, coding for a protein promoting cell migration, is highly overexpressed in class 2 tumors. The overall expression signature of class 2 tumors suggests they may originate from neuroectodermal stem cells.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22042019     DOI: 10.1159/000328270

Source DB:  PubMed          Journal:  Dev Ophthalmol        ISSN: 0250-3751


  5 in total

Review 1.  PleiotRHOpic: Rho pathways are essential for all stages of Neural Crest development.

Authors:  Philippe Fort; Eric Théveneau
Journal:  Small GTPases       Date:  2014-03-10

2.  Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target.

Authors:  Nabil Amirouchene-Angelozzi; Fariba Nemati; David Gentien; André Nicolas; Amaury Dumont; Guillaume Carita; Jacques Camonis; Laurence Desjardins; Nathalie Cassoux; Sophie Piperno-Neumann; Pascale Mariani; Xavier Sastre; Didier Decaudin; Sergio Roman-Roman
Journal:  Mol Oncol       Date:  2014-06-13       Impact factor: 6.603

Review 3.  Proteomics of uveal melanoma: a minireview.

Authors:  Søren K O Abildgaard; Henrik Vorum
Journal:  J Oncol       Date:  2013-09-03       Impact factor: 4.375

4.  Heterogeneity revealed by integrated genomic analysis uncovers a molecular switch in malignant uveal melanoma.

Authors:  Mark J de Lange; Sake I van Pelt; Mieke Versluis; Ekaterina S Jordanova; Wilma G M Kroes; Claudia Ruivenkamp; Sjoerd H van der Burg; Grégorius P M Luyten; Thorbald van Hall; Martine J Jager; Pieter A van der Velden
Journal:  Oncotarget       Date:  2015-11-10

5.  Heterogeneity of monosomy 3 in fine needle aspiration biopsy of choroidal melanoma.

Authors:  Melinda Y Chang; Nagesh P Rao; Barry L Burgess; Lariza Johnson; Tara A McCannel
Journal:  Mol Vis       Date:  2013-09-07       Impact factor: 2.367

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.